Kardiyovasküler hastalıklarda trombosit fonksiyon testleri: patofizyolojiden klinik yaklaşıma

Şermin Tetik; Koray Ak

Kardiyovasküler hastalıklarda trombosit fonksiyon testleri: patofizyolojiden klinik yaklaşıma

Year 2010, Volume: 32 Issue: 2, 264 - 274, 11.06.2010

Şermin Tetik , Koray Ak

Abstract

Özet

Trombositler, tromboz, hemostaz ve inflamasyonda büyük önemi olan hücrelerdir. Antitrombotik tedavi kardiyovasküler hastalıklara bağlı mortalite ve morbiditenin azaltılmasında önemlidir. Son yıllarda yapılan araştırmalarda, aspirin ve clopidogrel gibi antitrombotik ilaçlara karşı direnç üzerinde sıklıkla durulmaktadır. Bu nedenle kardiyovasküler hastalıklarda, antitrombotik ilaçların etkisini test etmek için trombosit fonksiyon testleri kullanması gerektirmektedir. Ancak in vivo trombosit fonksiyonları ve ex vivo trombosit fonksiyon testlerinin sonuçları arasındaki ilişki net olarak ortaya konulamamıştır. Bu derlemede, kardiyovasküler hastalıklarda kullanılan trombosit fonksiyon testleri, bu testlerin avantaj ve dezavantajları, antitrombotik tedaviye hastaların verdiği cevaplardaki çeşitliliğin incelenmesi ve direnç kanıtlarının tartışılması amaçlanmıştır.

Anahtar sözcükler: Trombosit fonksiyon testleri, antitrombotik tedavi, antitrombotik tedaviye direnç

Abstract

Platelets have significant functions in thrombosis, hemostasis and inflammation. Antithrombotic therapy has been proven to be important in reduction of mortality and morbidity related to cardiovascular diseases. Recently, many studies have been focused on antithrombotic drug resistance. With this regard, platelet function tests have been gaining more popularity to test the effectiveness of antithrombotic drugs. However, correlation between in vivo and ex vivo platelet functions has not been documented clearly. In this review, we aimed to discuss platelet function tests used in the diagnosis of cardiovascular diseases, advantages and disadvantages of these tests, altered responses to antithrombotic therapy and resistance to antithrombotic therapy.

Key words: Platelet function tests, antiplatelet treatment, resistance to antiplatelet treatment

Keywords

References

1. Yardımcı KT, Göker B, Şener A, Tetik Ş, Oba R, Ulutin ON: Trombositlerde Transport Sistemleri. 4. Ulusal Tromboz, Hemostaz ve Anjioloji Kongresi, 26-28 Eylül 2003, Edirne, 33-43.
2. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-6.
3. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
4. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27: 647-54.
5. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
6. Müller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
7. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-66.
8. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, Himbert D, Baruch D, Guillin MC, Steg PG. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005;45:1753-6.
9. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311-21.
10. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
11. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-6.
12. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004; 110: 489-93.
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
14. Tetik S, Eksioglu-Demiralp E, Yardimci KT: Effect of imatinib mesylate on platelet aggregation and fibrinogen binding. to isolated platelets. Adv Mol Med. 2005; 1: 165- 170.
15. S.M. Jafri, T. Ozawa, E. Mammen, T.B. Levine, C. Johnson, S. Goldstein. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993; 14: 205-12.
16. Rossi E, Casali B, Regolisti G, Davoli S, Perazzoli F, Negro A, Sani C, Tumiati B, Nicoli D. Increased plasma levels of platelet-derived growth factor (PDGF-BB+PDGF-AB) in patients with never-treated mild essential hypertension. Am J Hypertens 1998; 11: 1239- 43.
17. Nidorf S.M., Sturm M., Strophair J., Kendrew P.J., Taylor R.R. Whole blood aggregation, thromboxane release and the lyso derivative of platelet activating factor in myocardial infarction and unstable angina. Cardiovasc Res 1989; 23: 273-8.
18. Tetik S, Uras F, Ekşioğlu-Demiralp E, Turay Yardimci K. Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction. Clin Appl Thromb Hemost 2008: 14; 210-9.
19. Özsavcı D, Yardımcı KT, Yanıkkaya-Demirel G, Uras F, Hekim N, Ulutin ON. Apo A-1 binding to platelets detected by flow cytometry. Thromb Res 2001; 103: 117-22.
20. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyteplatelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-7.
21. Tetik S. “Dedection of Platelet Function with Cytometric Bead Array. VII. National Thrombosis, Hemosasis and Anjiology Congress, 4-6 May 2007, Cukurova University , School of Medicine-Eds. Orhan N. Ulutin, Adana (ISBN: 978-9944-5184-1-3), pp. 425
22. Minamino T, Kitakaze M, Sanada S, Asanuama H, Kurotobi T, Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998; 98: 1721-7.
23. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD. Increased platelet reactivity and circulating monocyte–platelet
aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31: 352-8.
24. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL 3rd, Goldberg RJ, Michelson AD. Circulating monocyte–platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-6.
25. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
26. Tetik S, Uras F, Yardimci KT. Purification and characterization of human platelet fibrinogen receptor the GpIIb/IIIa complex. Turkish Journal of Pharmaceutical Science. 2005; 2:155-62.
27. M. Griesshammer, H. Beneke, B. Nussbaumer, M. Grunewald, M. Bangerter, L. Bergmann. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res 1999;96:191-6.
28. Furman MI, Krueger LA, Frelinger AL 3rd, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000;84: 492-8.
29. Poley S, Mempel W. Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test. Eur J Haematol 2001; 66: 253-62.
30. Geiger J, Brich J, Hönig-Liedl P, Eigenthaler M, Schanzenbächer P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19: 2007-11.
31. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99: 620-5.
32. Ak K, Isbir CS, Tetik S, Atalan N, Tekeli A, Aljodi M, Civelek A, Arsan S. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. Journal of cardiac surgery 2009;24:404- 10.
33. Ak K, Atalan N, Tekeli A, Işbir S, Civelek A, Emekli N, Arsan S. Tromboelastografi ve kalp cerrahisinde kullanımı. Anadolu Kardiyol Derg 2008; 8: 154-62. 34. Willoughby S, Holmes A, Loscalzo. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002;1: 273-88.
35. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-7
36. E.J. Favaloro, G. Kershaw, M. Bukuya, M. Hertzberg, J. Koutts. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA- 100(R) and vWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-9.
37. M. Homoncik, A.D. Blann, U. Hollenstein, T. Pernerstorfer, H.G. Eichler, B. Jilma. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000;111: 1250-2.
38. M. Madan, S.D. Berkowitz, D.J. Christie. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001; 141: 226-233.
39. Frelinger AL 3rd, Hillman RS. Novel methods for assessing platelet function. Am Heart J 1998;135: S184-6.
40. Sanioglu S, Tetik S, Sokullu O, Deniz H, Aydemir N, Yilmaz M, Arslan IY, Bilgen F. Aspirin resistance after CABG. Thorac Cardiovasc Surg. 2009;57: 281-5.
41. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary arterydisease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-5.
42. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to lowdose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7.
43. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-5.
44. Tetik S, Ak K, Isbir S, Eksioglu-Demiralp, E, Arsan S, Iqbal I, Yardimci T. Clopidogrel Provides Significantly Greater Inhibition of Platelet Activity Than Aspirin When Combined With Atorvastatin After Coronary Artery Bypass Grafting: A Prospective Randomized Study. Clin Appl Thromb Hemost 2010; 162: 189-98.
45. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006; 48: 2186-91.
46. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-9.
47. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
48. Ronner E, Dykun Y, van den Brand MJ, van der Wieken LR, Simoons ML. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 1998; 19: 1608-16.